Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages
- PMID: 3085901
- DOI: 10.1007/BF02556715
Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages
Abstract
Two in vitro model systems were developed to facilitate investigation of the mechanisms by which bisphosphonates block bone resorption. These systems assess the cytotoxic and the migration inhibitory activities of bisphosphonates using mouse peritoneal macrophages as osteoclast surrogates. Several bisphosphonates, 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (AHPrBP), dichloromethylene bisphosphonate (Cl2MBP), 1-hydroxyethylidene-1,1-bisphosphonate (HEBP), 1-hydroxybutylidene-1,1-bisphosphonate (HBBP), 1-hydroxyhexylidene-1,1-bisphosphonate (HHBP), and 1-hydroxyoctylidene-1,1-bisphosphonate (HOBP), possess the same relative activities in these systems as they do in bone resorption systems. Calcium ion replacement studies using these systems demonstrated that bisphosphonates do not derive all their activity from sequestration of calcium ions from cells by chelation. Whereas calcium ion replacement abrogated the activity of EDTA, a nonbisphosphonate calcium chelator active in both systems, it failed to abrogate either the cytotoxic or the migration inhibitory effects of the bisphosphonates tested. Calcium ion replacement increased the migration inhibitory activity of all the bisphosphonates tested. Further, calcium ion replacement increased the cytotoxicity of HHBP and HOBP; however, it decreased the cytotoxicity of HEBP, HBBP, AHPrBP, and Cl2MBP.
Similar articles
-
Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro.Bone. 1987;8(3):179-89. doi: 10.1016/8756-3282(87)90018-4. Bone. 1987. PMID: 2955802
-
Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.Calcif Tissue Int. 1991 Dec;49(6):407-15. doi: 10.1007/BF02555852. Calcif Tissue Int. 1991. PMID: 1840176
-
Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.Calcif Tissue Int. 1986 Jun;38(6):342-9. doi: 10.1007/BF02555748. Calcif Tissue Int. 1986. PMID: 3089557
-
Assessment of bisphosphonate activity in vitro.Curr Pharm Des. 2010;16(27):2970-80. doi: 10.2174/138161210793563644. Curr Pharm Des. 2010. PMID: 20722618 Review.
-
The relationship between the chemistry and biological activity of the bisphosphonates.Bone. 2011 Jul;49(1):20-33. doi: 10.1016/j.bone.2011.03.774. Epub 2011 Apr 9. Bone. 2011. PMID: 21497677 Review.
Cited by
-
Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a placebo control trial in a tertiary level center.Rheumatol Int. 2012 Dec;32(12):3945-50. doi: 10.1007/s00296-011-2270-7. Epub 2011 Dec 27. Rheumatol Int. 2012. PMID: 22200806 Clinical Trial.
-
Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.J Clin Invest. 1991 Dec;88(6):2095-105. doi: 10.1172/JCI115539. J Clin Invest. 1991. PMID: 1661297 Free PMC article.
-
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.J Bone Miner Metab. 2009;27(4):464-70. doi: 10.1007/s00774-009-0055-9. Epub 2009 Mar 20. J Bone Miner Metab. 2009. PMID: 19301089 Clinical Trial.
-
Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ).Clin Oral Investig. 2016 Jun;20(5):1043-54. doi: 10.1007/s00784-015-1584-3. Epub 2015 Sep 9. Clin Oral Investig. 2016. PMID: 26349768
-
Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases.Clin Oral Investig. 2015 Mar;19(2):497-508. doi: 10.1007/s00784-014-1273-7. Epub 2014 Jun 24. Clin Oral Investig. 2015. PMID: 24957986
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources